Etelcalcetide Injection (Parsabiv™)

Coverage: etelcalcetide (Parsabiv) is covered for secondary hyperparathyroidism in adults (≥18) with CKD who are on hemodialysis and is excluded for patients <18, not on hemodialysis, those with corrected serum calcium <7.5 mg/dL or signs/symptoms of hypocalcemia, and for use concurrent with or within 7 days of cinacalcet. Key requirements: documentation of diagnosis, hemodialysis status, corrected Ca ≥7.5 mg/dL, PTH ≥300 pg/mL for initial approval (≥100 pg/mL for reauthorization), planned IV bolus dosing ≤15 mg up to three times weekly at end of dialysis, and approvals limited to 12 months.

"Age documentation demonstrating the patient is ≥ 18 years."

Sign up to see full coverage criteria, indications, and limitations.